Premium
SERIAL QUANTIFICATION OF MINIMAL RESIDUAL DISEASE OF t(8;21) ACUTE MYELOGENOUS LEUKAEMIA WITH RT‐COMPETITIVE PCR ASSAY
Author(s) -
MUTO AKIHIRO,
MORI SHIGEHISA,
MATSUSHITA HIROMICHI,
AWAYA NORIHIRO,
UENO HIRONORI,
TAKAYAMA NOBUYUKI,
OKAMOTO SHINICHIRO,
KIZAKI MASAHIRO,
IKEDA YASUO
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1877.x
Subject(s) - minimal residual disease , medicine , real time polymerase chain reaction , polymerase chain reaction , immunology , leukemia , oncology , biology , gene , genetics
The chromosomal translocation (8;21)(q22;q22) in the AML M2 subtype according to the FAB classification, results in the production of a novel fusion gene AML1/ETO . The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD). Recently, several studies on the detection of AML1/ETO transcripts in t(8;21) AML have been reported. However, the clinical significance of a small number of AML1/ETO transcripts by a reverse transcription–polymerase chain reaction (RT‐PCR) remains to be elucidated. We have developed a novel quantitative RT‐competitive PCR assay and evaluated the clinical usefulness of this method by the monitoring of MRD in eight patients with t(8;21) AML. In four patients in first continuous complete remission (CR) the value of MRD was always <0.1 fg of the competitor dose throughout their courses, whereas in four relapsed patients there was an increase in the value of MRD to <0.1 fg of the competitor dose before cytogenetic relapse. We conclude that the detection of the presence of cells with AML1/ETO fusion transcripts by our RT‐competitive PCR assay may be useful to monitor disease progression and to predict subsequent relapse.